Core Insights - The company reported a total revenue of 224 million yuan for the first half of 2025, marking an increase of 25.38 million yuan compared to the same period last year, achieving a 12.80% year-on-year growth [1] - The net profit attributable to shareholders reached 32.67 million yuan, an increase of 15.66 million yuan from the previous year, reflecting a significant year-on-year growth of 92.02% [1] - The net cash inflow from operating activities was 64.37 million yuan, ranking 31st among disclosed peers, with a year-on-year increase of 69.74% [1] Financial Metrics - The latest debt-to-asset ratio stands at 8.80%, ranking 5th among disclosed peers [3] - The gross profit margin is 60.10%, which is an increase of 1.00 percentage point compared to the same period last year, ranking 30th among peers [3] - The return on equity (ROE) is 1.84%, up by 0.84 percentage points year-on-year [3] - The diluted earnings per share (EPS) is 0.07 yuan, an increase of 0.03 yuan from the previous year, representing a year-on-year growth of 91.71% [3] - The total asset turnover ratio is 0.12 times, reflecting a year-on-year increase of 7.78% [3] - The inventory turnover ratio is 0.67 times, with a year-on-year increase of 3.02% [3] Shareholder Structure - The number of shareholders is 8,789, with the top ten shareholders holding 373 million shares, accounting for 79.35% of the total share capital [3] - The largest shareholder is Ningbo Meishan Bonded Port Area Fengjie Equity Investment Management Co., Ltd., holding 34.94% [3] - The second-largest shareholder is Micro Innovation Investment Holdings Co., Ltd., with a 32.71% stake [3]
微电生理(688351.SH):2025年中报净利润为3266.81万元、较去年同期上涨92.02%